ECSP088490A - ORAL PHARMACEUTICAL FORM THAT CONTAINS AS ACTIVE PRINCIPLES A PROTON PUMP INHIBITOR TOGETHER WITH ACETILSALICYL ACID - Google Patents
ORAL PHARMACEUTICAL FORM THAT CONTAINS AS ACTIVE PRINCIPLES A PROTON PUMP INHIBITOR TOGETHER WITH ACETILSALICYL ACIDInfo
- Publication number
- ECSP088490A ECSP088490A EC2008008490A ECSP088490A ECSP088490A EC SP088490 A ECSP088490 A EC SP088490A EC 2008008490 A EC2008008490 A EC 2008008490A EC SP088490 A ECSP088490 A EC SP088490A EC SP088490 A ECSP088490 A EC SP088490A
- Authority
- EC
- Ecuador
- Prior art keywords
- proton pump
- present
- acetylsalicylic acid
- pump inhibitor
- oral pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invención se refiere a una preparación farmacéutica oral para uso en la prevención y/o reducción de complicaciones gastrointestinales asociadas con el uso de ácido acetilsalicílico. La presente preparación comprende una forma de dosificación oral fija que comprende un inhibidor de la bomba de protones en combinación con ácido acetilsalicílico. Adicionalmente, la presente invención se refiere a un método de fabricación del mismo y su uso en medicina. La presente invención también se refiere a una combinación específica que comprende esomeprazol o una de sus sales alcalinas o una forma hidratada de cualquiera de ellas y ácido acetilsalicílico para uso como medicamento para la prevención de episodios vasculares tromboembólicos, como infarto de miocardio o accidente cerebrovascular, y la reducción y/o prevención de las complicaciones digestivas asociadas al tratamiento con ácido acetilsalicílico.The present invention relates to an oral pharmaceutical preparation for use in the prevention and / or reduction of gastrointestinal complications associated with the use of acetylsalicylic acid. The present preparation comprises a fixed oral dosage form comprising a proton pump inhibitor in combination with acetylsalicylic acid. Additionally, the present invention relates to a manufacturing method thereof and its use in medicine. The present invention also relates to a specific combination comprising esomeprazole or one of its alkaline salts or a hydrated form of any of them and acetylsalicylic acid for use as a medicament for the prevention of thromboembolic vascular events, such as myocardial infarction or stroke, and the reduction and / or prevention of digestive complications associated with acetylsalicylic acid treatment.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74098105P | 2005-11-30 | 2005-11-30 | |
US81888606P | 2006-07-06 | 2006-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088490A true ECSP088490A (en) | 2008-06-30 |
Family
ID=38092508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008490A ECSP088490A (en) | 2005-11-30 | 2008-05-30 | ORAL PHARMACEUTICAL FORM THAT CONTAINS AS ACTIVE PRINCIPLES A PROTON PUMP INHIBITOR TOGETHER WITH ACETILSALICYL ACID |
Country Status (14)
Country | Link |
---|---|
US (2) | US20100178334A1 (en) |
EP (1) | EP1957081A4 (en) |
JP (1) | JP2009517466A (en) |
KR (1) | KR20080070841A (en) |
AR (1) | AR057181A1 (en) |
AU (1) | AU2006321007A1 (en) |
CA (1) | CA2628907A1 (en) |
EC (1) | ECSP088490A (en) |
IL (1) | IL191312A0 (en) |
NO (1) | NO20082744L (en) |
RU (1) | RU2008121767A (en) |
TW (1) | TW200803871A (en) |
UY (1) | UY29975A1 (en) |
WO (1) | WO2007064274A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9600070D0 (en) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
SE510650C2 (en) | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
AR057181A1 (en) * | 2005-11-30 | 2007-11-21 | Astra Ab | NEW COMBINATION DOSAGE FORM |
US9265732B2 (en) * | 2006-03-06 | 2016-02-23 | Pozen Inc. | Dosage forms for administering combinations of drugs |
WO2009147178A2 (en) * | 2008-06-04 | 2009-12-10 | Nycomed Gmbh | Novel medical use of substituted pyridin-2-ylmethylsulphinyl-1h-benzimidazoles |
EA201100313A1 (en) | 2008-09-09 | 2011-10-31 | Астразенека Аб | METHOD OF DELIVERY OF THE PHARMACEUTICAL COMPOSITION TO THE PATIENT NEEDING THIS |
WO2010041276A1 (en) * | 2008-10-06 | 2010-04-15 | Jubilant Organosys Limited | Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof |
WO2010122583A2 (en) * | 2009-04-24 | 2010-10-28 | Rubicon Research Private Limited | Oral pharmaceutical compositions of acid labile substances |
US20100305163A1 (en) * | 2009-05-20 | 2010-12-02 | Pramod Dattatray Yedurkar | Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs |
WO2010151697A1 (en) * | 2009-06-25 | 2010-12-29 | Pozen Inc. | Method for treating a patient in need of aspirin therapy |
AU2010263304A1 (en) | 2009-06-25 | 2012-02-02 | Astrazeneca Ab | Method for treating a patient at risk for developing an NSAID-associated ulcer |
WO2011025673A1 (en) * | 2009-08-26 | 2011-03-03 | Aptapharma, Inc. | Multilayer minitablets |
WO2011144994A1 (en) * | 2010-05-21 | 2011-11-24 | Lupin Limited | Pharmaceutical compositions of nsaid and acid inhibitor |
MY180677A (en) * | 2010-12-03 | 2020-12-05 | Takeda Pharmaceuticals Co | Orally disintegrating tablet |
JP2014517046A (en) * | 2011-06-24 | 2014-07-17 | アセンダ ファーマ インコーポレイテッド | Method and improved pharmaceutical composition for improving the absorption of ester prodrugs |
TWI630002B (en) | 2011-11-30 | 2018-07-21 | 武田藥品工業股份有限公司 | Dry coated tablet |
WO2013101897A2 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
SG11201509439SA (en) * | 2013-05-21 | 2015-12-30 | Takeda Pharmaceutical | Orally disintegrable tablet |
WO2015150943A1 (en) * | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Pharmaceutical composition of nsaid and ppi or salt thereof |
TWI710379B (en) | 2015-07-30 | 2020-11-21 | 日商武田藥品工業股份有限公司 | Tablet |
JP7321744B2 (en) * | 2019-03-22 | 2023-08-07 | キョーリンリメディオ株式会社 | Enteric-coated solid preparation containing stabilized esomeprazole magnesium hydrate |
WO2023204397A1 (en) * | 2022-04-19 | 2023-10-26 | 한미약품 주식회사 | Pharmaceutical composition comprising acetylsalicylic acid and proton pump inhibitor |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4016744A (en) * | 1975-05-28 | 1977-04-12 | Hoffmann-La Roche Inc. | Applied instrumentation providing tabletting compression force |
US4263328A (en) * | 1979-10-26 | 1981-04-21 | General Foods Corporation | Tableted gasified candy |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US4948581A (en) * | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
US5204118A (en) * | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
MX9600857A (en) * | 1994-07-08 | 1997-06-28 | Astra Ab | Multiple unit tableted dosage form i. |
SE9600070D0 (en) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
US7029701B2 (en) * | 2000-09-11 | 2006-04-18 | Andrx Pharmaceuticals, Llc | Composition for the treatment and prevention of ischemic events |
US6544556B1 (en) * | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
US8206741B2 (en) * | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
CA2449098C (en) * | 2001-06-01 | 2010-01-05 | John R. Plachetka | Pharmaceutical compositions for the coordinated delivery of nsaids |
US6930099B2 (en) * | 2001-09-07 | 2005-08-16 | Advanced Medical Instruments | Composition for the treatment and prevention of endothelial dysfunction |
FR2845917B1 (en) * | 2002-10-21 | 2006-07-07 | Negma Gild | PHARMACEUTICAL COMPOSITION COMPRISING TENATOPRAZOLE AND ANTI-INFLAMMATORY |
US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
US20040131676A1 (en) * | 2002-12-20 | 2004-07-08 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
WO2004062552A2 (en) * | 2003-01-09 | 2004-07-29 | Galephar M/F | Pharmaceutical composition containing a nsaid and a benzimidazole derivative |
JP2005145894A (en) * | 2003-11-17 | 2005-06-09 | Takeda Chem Ind Ltd | Solid preparation |
US20050163847A1 (en) * | 2004-01-21 | 2005-07-28 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
AU2005213472A1 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
US20050227949A1 (en) * | 2004-04-07 | 2005-10-13 | Nasrola Edalatpour | Compositions and methods for treatment of viral and bacterial infections |
US20060177504A1 (en) * | 2005-02-08 | 2006-08-10 | Renjit Sundharadas | Combination pain medication |
AR057181A1 (en) * | 2005-11-30 | 2007-11-21 | Astra Ab | NEW COMBINATION DOSAGE FORM |
EP1965774A2 (en) * | 2005-12-30 | 2008-09-10 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
AR066677A1 (en) * | 2007-05-24 | 2009-09-02 | Novartis Ag | FORMATION OF PASSIREOTIDE. PHARMACEUTICAL COMPOSITION FOR PROLONGED RELEASE. MICROPARTICLES. |
-
2006
- 2006-11-27 AR ARP060105217A patent/AR057181A1/en not_active Application Discontinuation
- 2006-11-28 JP JP2008543231A patent/JP2009517466A/en active Pending
- 2006-11-28 US US12/094,519 patent/US20100178334A1/en not_active Abandoned
- 2006-11-28 EP EP06824483A patent/EP1957081A4/en not_active Withdrawn
- 2006-11-28 TW TW095144028A patent/TW200803871A/en unknown
- 2006-11-28 KR KR1020087012976A patent/KR20080070841A/en not_active Application Discontinuation
- 2006-11-28 RU RU2008121767/15A patent/RU2008121767A/en not_active Application Discontinuation
- 2006-11-28 AU AU2006321007A patent/AU2006321007A1/en not_active Abandoned
- 2006-11-28 US US11/563,812 patent/US20070122470A1/en not_active Abandoned
- 2006-11-28 CA CA002628907A patent/CA2628907A1/en not_active Abandoned
- 2006-11-28 WO PCT/SE2006/001349 patent/WO2007064274A1/en active Application Filing
- 2006-11-29 UY UY29975A patent/UY29975A1/en not_active Application Discontinuation
-
2008
- 2008-05-07 IL IL191312A patent/IL191312A0/en unknown
- 2008-05-30 EC EC2008008490A patent/ECSP088490A/en unknown
- 2008-06-17 NO NO20082744A patent/NO20082744L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2628907A1 (en) | 2007-06-07 |
WO2007064274A1 (en) | 2007-06-07 |
IL191312A0 (en) | 2008-12-29 |
NO20082744L (en) | 2008-08-28 |
KR20080070841A (en) | 2008-07-31 |
RU2008121767A (en) | 2010-01-10 |
EP1957081A1 (en) | 2008-08-20 |
AR057181A1 (en) | 2007-11-21 |
AU2006321007A1 (en) | 2007-06-07 |
EP1957081A4 (en) | 2013-01-02 |
US20100178334A1 (en) | 2010-07-15 |
JP2009517466A (en) | 2009-04-30 |
US20070122470A1 (en) | 2007-05-31 |
TW200803871A (en) | 2008-01-16 |
UY29975A1 (en) | 2007-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088490A (en) | ORAL PHARMACEUTICAL FORM THAT CONTAINS AS ACTIVE PRINCIPLES A PROTON PUMP INHIBITOR TOGETHER WITH ACETILSALICYL ACID | |
ES2524320T3 (en) | Composition for the prevention or treatment of disease associated with thrombus or embolus | |
AR082091A1 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PIOGLITAZONA AND LINAGLIPTINE AND PREPARATION PROCEDURE | |
GT200600445A (en) | SOLID PHARMACEUTICAL PRESENTATION FORMS OF ORAL ADMINISTRATION WITH QUICK RELEASE OF THE ACTIVE PRINCIPLE. | |
CY1114190T1 (en) | NEW FORM OF RASKADOTRIL ADMINISTRATION | |
GT201300309A (en) | MODIFIED RELEASE OF 4-METHYL-3 - [[4- (3-PYRIDINYL) -2- PYRIMIDINYL] -AMINO] -N- [5- (4-METHYL -1H-IMIDAZOL-1-IL) -3- (TRIFLUORO -METIL) -PENYL] -BANZAMIDE SOLUBILIZED USING ORGANIC ACIDS | |
CR20140019A (en) | PROCEDURE FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION IN THE FORM OF PROLONGED RELEASE TABLETS CONTAINING PYRFENIDONE AND ITS APPLICATION IN THE REGRESSION OF THE CHRONIC REAL INSUFFICIENCY, MAMMARY CAPSULAR CONTRACTURE AND ... | |
AR075369A1 (en) | COMPRESSED FOR COMBINATION THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS. | |
CO6491060A2 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES | |
CO6640264A2 (en) | Combination of active loaded granules with additional assets | |
AR086395A1 (en) | PACKAGE FOR TREATMENT OF PATHOLOGIES | |
CO6300935A2 (en) | ORAL AND INJECTABLE FORMULATIONS OF TETRACICLINE COMPOUNDS | |
CO6420389A2 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | |
AR075041A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ALEGLITAZAR, PROCESS, USE. | |
UY31662A1 (en) | COMPOSITIONS OF RANITIDINE TABLETS OF ORAL DISINTEGRATION AND ITS METHODS OF ELABORATION. | |
UY31826A (en) | PEPTIDE COMPOUND AND ITS USE | |
CL2013003176A1 (en) | Sustained-release oral pharmaceutical formulation comprising two tablets containing 1000 mg of paracetamol, which is present in a sustained-release layer and another of immediate release, in a proportion of paracetamol per layer of 80-90%: 10-20% , where the unit dose comprises 2000 mg paracetamol. | |
UY29989A1 (en) | PHARMACEUTICAL COMPOSITIONS OF HYPNOTIC AGENTS OF SHORT ACTION IN THE FORM OF A MODIFIED RELEASE AND PROCEDURES TO PREPARE SUCH FORMULATIONS | |
AR085431A1 (en) | DOXYLAMINE RESINATE COMPLEX | |
ES2526359T3 (en) | Oral galenic formulation comprising ketorolac and B vitamins, in which vitamin B6 is in an external layer separated from the rest of active ingredients | |
AR085399A1 (en) | ANTITUMORAL COMBINATION INCLUDING CABAZITAXEL AND CISPLATINO | |
AR061487A1 (en) | A PHARMACEUTICAL COMPOSITION IN THE FORM OF MULTI-PAPER TETRACICLINE COMPRESSED | |
UY37518A (en) | DOSED FORMS OF MODIFIED GASTRORETENTIVE RELEASE FOR OPROZOMIB AND PROCESS FOR MANUFACTURING | |
SV2006002017A (en) | PIPERAZINAS DERIVED FROM UREA | |
ES2637852T3 (en) | Lactoferrin for use in the treatment of preterm birth and miscarriage |